Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;53(7):2795-2806.
doi: 10.1007/s10508-024-02886-6. Epub 2024 Jun 7.

Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China

Lu Liu  1 , Yuhua Ruan  2   3 , Shiwen Chen  1 , Hongyang Tang  4 , Junhui Liu  4 , Yu Jiang  1 , Hengyan Pei  1 , Tengda Huang  1 , Guanghua Lan  3   5 , Yihong Xie  6
Affiliations

Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China

Lu Liu et al. Arch Sex Behav. 2024 Jul.

Abstract

Cabotegravir (CAB-LA), the first long-acting injectable pre-exposure prophylaxis (PrEP), has been approved for use in the USA and is not currently on the market in China. However, willingness to use CAB-LA and associated factors among men who have sex with men (MSM) have not yet been evaluated in China. A cross-sectional study was conducted in Guangxi, China, in 2022 recruiting 1,006 MSM. Their mean age was 30.2 years, 74.2% had college or above education, and 48.6% had a monthly income between 3,000 and 5,999 Chinese yuan (CNY). Most (73.4%) had previously heard of PrEP while few (8.3%) had ever used this type of preventative medication. Willingness to use CAB-LA was 79.8% and was positively associated with eight variables: younger age, being married to a woman, having a low monthly income, having six or more male partners in the past six months, having only regular male partners in the past month, having a high perceived risk of HIV infection, and history of using PrEP. Ten other variables were not significantly associated with willingness to use CAB-LA. Among 894 participants who were willing to use or did not definitely reject using CAB-LA, the main concerns about CAB-LA were its side effects (90.2%), efficacy (63.6%), and high cost (58.2%). Only 14.7% were willing to pay more than 1,200 CNY (~US$180) every two months to use CAB-LA. The preferred injection places were centers for disease control facilities, hospitals, and social organizations. Many (89.0%) said that they would recommend CAB-LA to their male sexual partners. We conclude that willingness to use CAB-LA was high among MSM in Guangxi. However, implementation of CAB-LA faces tough challenges due to its high cost and the low use of PrEP. Peer education may play a large role in the implementation of CAB-LA in China.

Keywords: China; HIV/AIDS; Long-acting injectable Cabotegravir; Men who have sex with men; Pre-exposure prophylaxis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Binson, D., Pollack, L. M., Blair, J., & Woods, W. J. (2010). HIV transmission risk at a gay bathhouse. Journal of Sex Research, 47(6), 580–588. https://doi.org/10.1080/00224490903216755 - DOI - PubMed - PMC
    1. Chan, C., Vaccher, S., Fraser, D., Grulich, A. E., Holt, M., Zablotska-Manos, I., Prestage, G. P., & Bavinton, B. R. (2022). Preferences for current and future PrEP modalities among PrEP-experienced gay and bisexual men in Australia. AIDS and Behavior, 26(1), 88–95. https://doi.org/10.1007/s10461-021-03344-3 - DOI - PubMed
    1. Chou, R., Evans, C., Hoverman, A., Sun, C., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019). Preexposure prophylaxis for the prevention of HIV infection: Evidence report and systematic review for the US Preventive Services Task Force. Journal of the American Medical Association, 321(22), 2214–2230. https://doi.org/10.1001/jama.2019.2591 - DOI - PubMed
    1. Chuai, Z., Zhang, Y., Zhao, Y., Yan, J., Sun, Z., Wang, Y., Jiao, Y., & Wang, F. (2020). Latest AIDS epidemic in global and China. Journal of Infectious Disease Information, 33(06), 501–503. https://doi.org/10.3969/j.issn.1007-8134.2020.06.002 - DOI
    1. Del Rio, C. (2017). The global HIV epidemic: What the pathologist needs to know. Seminars in Diagnostic Pathology, 34(4), 314–317. https://doi.org/10.1053/j.semdp.2017.05.001 - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources